With pipeline setbacks mounting, United snares priority voucher for inhaled formulation of PAH med Tyvaso

With pipeline setbacks mounting, United snares priority voucher for inhaled formulation of PAH med Tyvaso

Source: 
Endpoints
snippet: 

Despite a big lead in pulmonary arterial hyptertension, United Therapeutics is under the gun as it looks to stave off competitors and build a successful expansion over in oncology. So far, those results have been mixed. But now, United is on the cusp of adding a new formulation to its successful Tyvaso franchise that could spur growth.